Thursday, March 26, 2020 7:46:33 PM
If you're referring to law suits,
TEVA has already settled some of those, and it didn't cost all that much.
I think that one of them -- maybe the largest -- hasn't been settled, and it's court date has been delayed. And that would probably be because it is outrageous (as are most things that layers try to do, as they are the bullies in the playground and aim to get rich by overcharging for their services).
The only lawyers that I like are the patent lawyers; but you don't really need them because all they do is follow a boiler plate layout and ask the inventor for all the information to fill in all the blanks. In other words, they are glorified secretaries in a suit.
TEVA has already settled some of those, and it didn't cost all that much.
I think that one of them -- maybe the largest -- hasn't been settled, and it's court date has been delayed. And that would probably be because it is outrageous (as are most things that layers try to do, as they are the bullies in the playground and aim to get rich by overcharging for their services).
The only lawyers that I like are the patent lawyers; but you don't really need them because all they do is follow a boiler plate layout and ask the inventor for all the information to fill in all the blanks. In other words, they are glorified secretaries in a suit.
Recent TEVA News
- Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics • GlobeNewswire Inc. • 04/14/2026 12:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/31/2026 08:43:03 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/31/2026 08:41:07 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/31/2026 08:38:29 PM
- Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab) • GlobeNewswire Inc. • 03/30/2026 12:00:00 PM
- Teva Releases Q1 2026 Aide Memoire • GlobeNewswire Inc. • 03/19/2026 08:30:00 PM
- Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026 • GlobeNewswire Inc. • 03/19/2026 08:30:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2026 10:36:38 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2026 10:28:47 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2026 10:22:25 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/03/2026 10:46:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/03/2026 10:34:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/03/2026 10:25:46 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/03/2026 10:13:29 PM
- Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug • GlobeNewswire Inc. • 03/03/2026 10:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/02/2026 09:01:38 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/26/2026 09:11:04 PM
- Teva to Present at the Upcoming Investor Conferences in March • GlobeNewswire Inc. • 02/24/2026 09:30:00 PM
- Medincell : La FDA américaine accepte le dossier de demande de mise sur le marché déposé par Teva pour l’Olanzapine LAI • Business Wire • 02/20/2026 08:37:00 PM
- Medincell: U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults • Business Wire • 02/20/2026 08:37:00 PM
- U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults • GlobeNewswire Inc. • 02/20/2026 07:43:11 PM
- Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease • GlobeNewswire Inc. • 02/17/2026 11:00:00 AM
- Teva Canada Announces Approval of Expanded Indication of [Pr]AJOVY® (fremanezumab solution for subcutaneous injection), the First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine • PR Newswire (Canada) • 02/04/2026 01:05:00 PM
- Teva Canada annonce l'approbation de l'indication élargie de [Pr]AJOVY[MD] (frémanézumab, solution pour injection sous cutanée), le premier traitement préventif anti-CGRP indiqué pour la migraine épisodique pédiatrique • PR Newswire (Canada) • 02/04/2026 01:05:00 PM
